Golf

PGA Tour suspends Robert Garrigus for violating drug coverage

Former top-50 participant Robert Garrigus has been suspended by the PGA Tour for 3 months for violating the Tour’s anti-doping program, “testing optimistic for a substance recognized as a drug of abuse.”

In keeping with Garrigus, the drug he examined optimistic for was marijuana, which, as he famous in an announcement on Twitter, is authorized in lots of states however not permitted by the Tour. Garrigus apologized to his household and mates, acknowledging he failed this take a look at “after an extended interval of sobriety,” and stated he intends to “take this time away from golf to be with my household and work on regaining my sobriety.”

That is my assertion relating to my suspension by the PGA TOUR. pic.twitter.com/isatq7c9Mx

— Robert Garrigus (@garrigus_robert) March 22, 2019

Garrigus is presently the 450th-ranked participant on the earth, successful on Tour again in 2010, and has continued to play on Tour as just lately as final month. He has struggled with sobriety in his profession, with each alcohol and marijuana, discussing the problem at size with GOLF.com in March 2012, even admitting to smoking mid-round on the Nationwide Tour (now the Net.com Tour) again in 2002.

“It’s not a performance-enhancing drug,” Garrigus stated on the time. “They shouldn’t even be testing for it out right here. It’s one thing lots of people use.”

In keeping with the Related Press, Garrigus is the primary participant to be suspended for a “drug of abuse.” The Tour now publicly studies suspensions associated to medicine of abuse, which it didn’t do previous to a June 2017 change to this system.

The most recent version of the Tour’s anti-doping coverage is just not accessible on-line, however the USGA hyperlinks to an October 2017 model which lists three completely different banned substances as medicine of abuse. (See under.) The anti-doping program is up to date by the Tour when deemed obligatory. You could find the October 2017 model of it right here.

 

Related Articles